Interact with Decipher Biosciences experts at conferences, tradeshows, and online events to keep current on the latest news and developments.

Filter by:

No showcased events for March 2021.


Choose a

American Urological Association (AUA)

AUA 2019 - Chicago, IL

A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome

Response to Apalutamide (APA) among patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN by Decipher Genomic Classifier (GC) score

Genomic expression and prognostic significance of stromal microenvironment in primary prostate cancer

Decipher Biopsy genomic test related to Gleason grade group independent of prostate imaging reporting and data system version 2

A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy

Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy

Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of Decipher and PAM50 tests among different age groups

Correlation between MRI phenotypes and a genomic classifier of prostate cancer

Prospective randomized trial of gene expression classifier utility in men at high risk of recurrence following radical prostatectomy

HOXB13 expression and its role in prostate cancer progression and neuroendocrine differentiation

Impact of SPOP mutation on prostate cancer prognosis

Network-based transcriptomic analysis identifies gene signatures associated with mpMRI-visible prostate cancer

ASCO Genitourinary Cancers Symposium

ASCO GU 2020 - San Fransisco, CA

Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial

Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED

Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy

Association of an immune-gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC)

Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC)

Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design

Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests

INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer

Tumor cell intrinsic androgen biosynthesis by 3β-hydroxy steroid dehydrogenase (HSD3B1) to modulate radiosensitivity in prostate cancer cells

Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis

Decipher SM Icons

Please enter your name & email address below to download your PDF:

  • This field is for validation purposes and should be left unchanged.